Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

TenNor Therapeutics Raises $71M in Hong Kong IPO – Antimicrobial Pipeline Targets H. pylori and Implant-Associated Infections

Fineline Cube May 14, 2026
Company Deals Drug

Fosun Pharma Secures Global Rights to AriBio’s Alzheimer’s Drug AR1001 in $240M Deal – PDE-5 Inhibitor Shows Promise in Phase III

Fineline Cube May 14, 2026
Company Deals

Merck & Co. Forges Four Strategic Partnerships with Chinese Biotechs to Advance Autoimmune and Oncology Pipeline Through MCICC Platform

Fineline Cube May 14, 2026
Company Deals

Shanghai Immunocan Biotech Secures RMB 250M Series A Led by Vivo Capital to Advance Gene-Edited Antibody Discovery Platforms

Fineline Cube May 13, 2026
Company Deals

Shenzhen Weiguang Biological to Raise RMB 1.5B in Private Placement to Fund Smart Industrial Base Expansion

Fineline Cube May 13, 2026
Policy / Regulatory

China’s CDE Reports Record Drug Review Activity in 2025 – Breakthrough Therapy Designations Surge 11% as Regulatory Filings Hit 20,149

Fineline Cube May 14, 2026
Company Drug

Hansoh Pharma Receives NMPA Approval for HS-10541 Phase I Trial – Category 1 KRAS G12C Inhibitor Targets Advanced Solid Tumors

Fineline Cube May 14, 2026
Company Drug

Pfizer’s Hympavzi Gains European Approval for Hemophilia with Inhibitors – Novel TFPI-Targeting Therapy Offers Weekly Subcutaneous Alternative to Factor Replacement

Fineline Cube May 14, 2026
Company Drug

Merck Ends Phase III Keytruda Studies in NSCLC and cSCC Due to Insufficient Results

Fineline Cube Aug 30, 2024

US-based Merck, Sharp & Dohme Inc. (NYSE: MRK) announced the discontinuation of two Phase III...

Company

BioMarin to Cut 225 Jobs Amid Challenges in Gene Therapy Commercialization

Fineline Cube Aug 30, 2024

US-based BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) is navigating a challenging period marked by difficulties in...

Company Deals Medical Device

MicroPort CardioFlow to Acquire RMB 380 Million Shanghai Assets for Global HQ Expansion

Fineline Cube Aug 30, 2024

China-based MicroPort Scientific Corp. (HKG: 0853) has announced that its spin-off, MicroPort CardioFlow Medtech Co.,...

Company Drug

Tonghua Golden-Horse, UCB Seek China Approvals for Alzheimer’s, Myasthenia Gravis Drugs

Fineline Cube Aug 30, 2024

China’s Tonghua Golden-Horse Pharmaceutical Industry Co. Ltd. and Belgium-based UCB (FRA: UNC) are seeking marketing...

Company

Dizal Pharmaceutical’s Financial Turnaround Continues with 33% Net Loss Reduction in H1 2024

Fineline Cube Aug 30, 2024

Dizal Pharmaceutical Co., Ltd, a pharmaceutical entity listed in Shanghai (SHA: 688192), has unveiled its...

Company Drug

Doma Biopharmaceutical Receives FDA Clearance for Phase I Trial of EGFR-MET Targeting ADC, DM005

Fineline Cube Aug 30, 2024

Doma Biopharmaceutical (Suzhou) Co., Ltd, a Chinese pharmaceutical firm, has received approval from the U.S....

Company Drug

Jiyuan Biotechnology’s Stem Cell Therapy for Type 2 Diabetes Gains NMPA Tacit Approval for Clinical Trials

Fineline Cube Aug 30, 2024

BEIJING—Jiyuan Biotechnology, a leading Chinese biopharmaceutical company, has secured tacit clinical trial approval from the...

Company Deals

AstraZeneca Boosts Investment in Qingdao Aerosol Production Hub to $750 Million

Fineline Cube Aug 30, 2024

QINGDAO—AstraZeneca (NASDAQ: AZN), a leading UK-based pharmaceutical company, has announced a further investment in its...

Company Medical Device

NMPA Suspends Jeisys Medical Inc.’s Nd:YAG Laser Equipment Over Quality Concerns

Fineline Cube Aug 30, 2024

BEIJING—The National Medical Products Administration (NMPA) of China has issued a notification to immediately suspend...

Company Drug

CNGB Virogin’s VG161 On Track for Breakthrough Designation in China for Advanced Liver Cancer

Fineline Cube Aug 30, 2024

BEIJING—CNGB Virogin, a joint venture between Virogin Biotech and China National Biotec Group, is poised...

Policy / Regulatory

China’s Healthcare Statistics Show Improvements in Life Expectancy and Access to Medical Services

Fineline Cube Aug 30, 2024

BEIJING—The National Health Commission (NHC) of China has published the “China’s Healthcare Statistical Communique 2023,”...

Company

Mindray Bio-Medical Electronics Reports 11.12% YOY Revenue Growth in 2024H1

Fineline Cube Aug 30, 2024

SHENZHEN—Mindray Bio-Medical Electronics Co., Ltd (SHE: 300760) has announced its financial results for the first...

Company

Hua Medicine’s 2024H1 Revenues Surge on HuaTangNing Sales; Path to Profitability in Sight

Fineline Cube Aug 30, 2024

HONG KONG—Hua Medicine (HKG: 2552), a China-based pharmaceutical company, has announced its financial results for...

R&D

American Government Funds Bolster Chinese Inventors’ Patents, According to USPTO Data

Fineline Cube Aug 30, 2024

WASHINGTON—A Reuters investigation into the United States Patent and Trademark Office (USPTO) data has uncovered...

Company

GeneQuantum Appoints Dr. Lingyu Zhu as Chief Business Strategy and Development Officer

Fineline Cube Aug 30, 2024

SUZHOU—GeneQuantum, a leading player in the biotech industry known for its cutting-edge enzymatic site-specific conjugation...

Policy / Regulatory

Jiangxi Healthcare Security Administration Launches Initiative to Widen Drug Availability

Fineline Cube Aug 29, 2024

JIANGXI—In a strategic move to enhance drug accessibility, the Healthcare Security Administration (HSA) bureau of...

Company Legal / IP

China’s Supreme Court Deals Blow to Sanofi’s Aubagio, Confirms Patent Cancellation

Fineline Cube Aug 29, 2024

BEIJING—In a recent development for the pharmaceutical industry, Sanofi’s multiple sclerosis therapy Aubagio (teriflunomide) has...

Company Deals

Pfizer Partners with Quotient Therapeutics for Somatic Mutations Research in Cardiovascular and Renal Diseases

Fineline Cube Aug 29, 2024

NEW YORK—Pfizer Inc., a pharmaceutical giant listed on the New York Stock Exchange (NYSE: PFE),...

Company Deals

Sackler-Owned Mundipharma Fails to Secure $1 Billion Valuation for China Unit

Fineline Cube Aug 29, 2024

LONDON—Mundipharma International Ltd., the UK-based pharmaceutical firm with ties to the Sackler family of the...

Company Drug

Sinopharm and Ruidio Pharmaceutical Advance in Priority Review for Innovative Drugs and Vaccines

Fineline Cube Aug 29, 2024

BEIJING—The Center for Drug Evaluation (CDE) has indicated that two Chinese companies, Foshan Ruidio Pharmaceutical...

Posts pagination

1 … 305 306 307 … 666

Recent updates

  • Hansoh Pharma Receives NMPA Approval for HS-10541 Phase I Trial – Category 1 KRAS G12C Inhibitor Targets Advanced Solid Tumors
  • Basecare Medical Device Secures NMPA Approval for Gems Embryo Culture Medium – Chinese IVF Specialist Completes Global Regulatory Triad
  • Pfizer’s Hympavzi Gains European Approval for Hemophilia with Inhibitors – Novel TFPI-Targeting Therapy Offers Weekly Subcutaneous Alternative to Factor Replacement
  • Henlius Biotech Secures Australian TGA Approval for HLX48 Phase I Trial – Novel EGFR/c-Met Bispecific ADC Targets Advanced Solid Tumors
  • Takeda Reports $28.5B Revenue in FY2025 Despite Vyvanse Patent Cliff – 78% Net Profit Surge Amid $1.26B Restructuring Plan
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hansoh Pharma Receives NMPA Approval for HS-10541 Phase I Trial – Category 1 KRAS G12C Inhibitor Targets Advanced Solid Tumors

Company Medical Device

Basecare Medical Device Secures NMPA Approval for Gems Embryo Culture Medium – Chinese IVF Specialist Completes Global Regulatory Triad

Company Drug

Pfizer’s Hympavzi Gains European Approval for Hemophilia with Inhibitors – Novel TFPI-Targeting Therapy Offers Weekly Subcutaneous Alternative to Factor Replacement

Company Drug

Henlius Biotech Secures Australian TGA Approval for HLX48 Phase I Trial – Novel EGFR/c-Met Bispecific ADC Targets Advanced Solid Tumors

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.